«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年04期

页码:

298-301

栏目:

出版日期:

2018-07-20

文章信息/Info

Title:

Biological safety evaluation on thiolated carboxymethyl chitosan-carried methazolamide nanoparticle eye drop

作者:

李光远¹; 2; 娄建石¹; 陈 斌²; 李 楠²; 王晓辉²; 刘佩莉²; 祝君梅²

1.天津医科大学药理学系，天津 300070； 2.天津市医药科学研究所医用生物材料监测研究中心，天津 300020

Author(s):

LI Guang-yuan¹; 2;  LOU Jian-shi¹;  CHEN Bin ²;  LI Nan ²;  WANG Xiao-hui²;  LIU Pei-li²;  ZHU Jun-mei²

1.Department of Pharmacology, Tianjin Medical University, Tianjin 300070, China; 2.Medical Biological Material Supervision and Research Center, Tianjin Institute of Medical and Pharmaceutical Sciences, Tianjin 300020, China

关键词:

纳米球; 醋甲唑胺; 巯基化羧甲基壳聚糖; 生物相容性

Keywords:

nanoparticles;  methazolamide;  thiolatedcarboxymethyl chitosan;  biological safety evaluation

分类号:

R9

DOI:

-

文献标志码:

Ａ

摘要:

目的：研究巯基化羧甲基壳聚糖载醋甲唑胺纳米球滴眼剂的生物相容性。方法：以巯基化羧甲基壳聚糖为载体，包裹醋甲唑胺得到载药纳米球，制备成滴眼剂。采用迟发超敏试验、细胞毒性试验(MTT法和LDH法)，对该滴眼剂进行生物安全性评价。结果：醋甲唑胺纳米球滴眼剂对豚鼠皮肤未出现红斑水肿现象，无致敏性，细胞毒性反应为2级，LDH释放率为37.09 %，MTT试验和LDH试验IC50结果为0.24 g/mL和0.54 g/mL。结论：醋甲唑胺纳米球滴眼剂具有良好的生物相容性。

Abstract:

Objective: To test the biological of thiolatedcarboxymethyl chitosan(tCMCS)-carried methazolamide(MTZ). Methods：This study used tCMCS as a drug carrier to prepare thiolatedcarboxymethyl chitosan-carried methazolamide nanoparticle eye drop (tCMCS-MTZ-NED). To measure the delayed-type hypersensitivity response, cytotoxicity test (MTT and LDH) of the tCMCS-MTZ-NED was performed. Results：tCMCS-MTZ-NED is not the sensitinogen for guinea pig (both integration and ratio of skin reaction are 0), cytotoxicity was grade 2, the release rate of LDH was 37.09%, the IC50 tested by refined MTT assay and LDH assay were 0.24 g/mL and 0.54 g/mL.Conclusion:tCMCS-MTZ-NED has good biocompatibility.

参考文献/References:

[1] Matalliotakis M，Goulielmos G N，Kalogiannidis I，et al. Extra pelvic endometriosis: Retrospective analysis on 200 cases in two different countries[J]. Eur J Obstet Gynecol Reprod Biol，2017，217: 34
[2] Chang C Y，Lai M T，Chen Y，et al. Up-regulation of ribosome biogenesis by MIR196A2 genetic variation promotes endometriosis development and progression[J]. Oncotarget，2016，7(47): 76713
[3] Ecker A M，Donnellan N M，Shepherd J P. Abdominal wall endometriosis: 12 years of experience at a large academic institution[J]. Am J Obstet Gynecol，2014，211(4): 363
[4] Gachabayov M，Horta R，Afanasyev D. et al abdominal wall endometrioma:our experience in vladimir,Russia[J]. Niger Med J，2016，57(6): 329
[5] Wang P H，Juang C M，Chao H T，et al. Wound endometriosis: risk factor evaluation and treatment[J]. J Chin Med Assoc，2003，66(2): 113
[6] 吴珍珍，郭钰珍.腹壁子宫内膜异位症疾病特征Meta分析[J].中国实用妇科与产科杂志，2014，30(10):802
[7] Da Y L，Trigo L，Benetti-Pinto C L，et al. Evaluation of cases of abdominal wall endometriosis at universidadeestadual de campinas in a period of 10 years[J]. Rev Bras GinecolObstet，2017，39(8): 403
[8] Vuksic T，Rastovic P，Dragisic V，et al.Abdominal Wall Endometrioma after Laparoscopic Operation of Uterine Endometriosis[J]. Case Rep Surg，2016，2016: 579
[9] Touleimat S，Darwish B，Vassilieff M，et al. Abdominal wall endometriosis following cesarean section:a study of the growth rate of parietal endometriosis implants[J]. Minerva Ginecol，2017，69(5): 440
[10] Pas K，Joanna S M，Renata R，et al. Prospective study concerning 71 cases of caesarean scar endometriosis(CSE)[J]. J Obstet Gynaecol (Lahore)，2017，37(6): 775
[11] Savelli L，Manuzzi L，Di Donato N，et al. CeccaroniM，etal.endometriosis of the abdominal wall:ultrasonographic and doppler characteristics[J]. Ultrasound Obstet Gynecol，2012，39(3): 336
[12] Francica G. Reliable clinical and sonographic findings in the diagnosis of abdominal wall endometriosis near cesarean section scar[J]. World J Radiol，2012，4（4）: 135
[13] Yarmish G，Sala E，Goldman D A，et al. Abdominal wall endometriosis: differentiation from other masses using CT features[J]. ABDOMINAL RADIOLOGY，2017，42（5）: 1517
[14] Busard M H，Mijatovic V，Kuijk C，et al. Appearance of abdominal wall endometriosis on Mrimaging[J]. Eur Radiol，2010，20（5）: 1267
[15] Kobayashi H，Miyake W，Yamashita M，et al. The mechanism of the increase in the serum CA125 concentration in patients with endometriosis[J]. Nihon Sanka Fujinka Gakkai Zasshi，1988，40（4）: 467
[16] Karimi-Zarchi M，Dehshiri-Zadeh N，Sekhavat L，et al. Correlation of CA-125 serum level and clinico-pathological characteristic of patients with endometriosis[J]. Int J Reprod Biomed（Yazd），2016， 14（11）: 713
[17] Zhu X，Chen L，Deng X，et al. A comparison between high-intensity focused ultrasound and surgical treatment for the management of abdominal wall endometriosis[J]. BJOG，2017，124（3，SI）: 53
[18] Maillot J，Brun J L，Dubuisson V，et al. Mid-term outcomes after percutaneous cryoablation of symptomatic abdominal wall endometriosis: comparison with surgery alone in a single institution[J]. Eur Radiol，2017，27（10）: 4298
[19] Siddiqui Z A，Husain F，Siddiqui Z，et al. Port site endometrioma: a rare cause of abdominal wall pain following laparoscopic surgery[J]. BMJ Case Rep，2017: 2017
[20] Sosa-Duran E E，Aboharp-Hasan Z，Mendoza-Morales R C，et al. Clear cell adenocarcinoma arising from abdominal wall endometriosis[J]. Cir Cir，2016，84（3）: 245
[21] FargasFabregas F，Cusido M. Malignant transformation of abdominal wall endometriosis with lymph node metastasis: Case report and review of literature[J]. Gynecol Oncol Case Rep，2014，8: 10
[22] Graur F，Mois E，Elisei R，et al. Malignant endometriosis of the abdominal wall[J]. Ann Ital Chir，2017，6（1）: 180

相似文献/References:

备注/Memo

备注/Memo:

-

常用功能

更新日期/Last Update: 2018-07-20